Screener
Halozyme Therapeutics HALO Royalties — Revenue from Contract with Customer, Excluding Assessed Tax
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Halozyme Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001159036-26-000104
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Revenues | ||||
| Royalties | $307,699 | $205,639 | $548,380 | $373,831 |
| Product sales, net | 129,626 | 81,510 | 260,050 | 159,551 |
| Revenues under collaborative agreements | 43,674 | 38,570 | 49,277 | 57,198 |
| Total revenues | 480,999 | 325,719 | 857,707 | 590,580 |
| Operating expenses | ||||
| Cost of sales | 79,171 | 46,359 | 158,409 | 94,762 |
| Amortization of intangibles | 29,512 | 17,762 | 59,024 | 35,524 |
Item 1. Financial Statements
FAQ
- What is Halozyme Therapeutics's royalties — revenue from contract with customer, excluding assessed tax?
- Halozyme Therapeutics (HALO) reported royalties — revenue from contract with customer, excluding assessed tax of $307.7M in Q2 2026.
- How has Halozyme Therapeutics's royalties — revenue from contract with customer, excluding assessed tax changed year-over-year?
- Halozyme Therapeutics's royalties — revenue from contract with customer, excluding assessed tax increased by 49.6% year-over-year, from $205.64M to $307.7M.
- What is the long-term trend for Halozyme Therapeutics's royalties — revenue from contract with customer, excluding assessed tax?
- Over 4 years (2021 to 2025), Halozyme Therapeutics's royalties — revenue from contract with customer, excluding assessed tax has grown at a 43.6% compound annual growth rate (CAGR), from $203.9M to $867.84M.
- What does royalties — revenue from contract with customer, excluding assessed tax mean?
- This metric represents the total gross revenue recognized from royalty-bearing intellectual property licensing agreements, excluding any sales-based taxes. It reflects the economic value generated by the company's proprietary technology platform as utilized by commercial partners. This is a primary indicator of the underlying market adoption and commercial success of products incorporating the company's licensed technology.
Ask your AI about Halozyme Therapeutics's royalties — revenue from contract with customer, excluding assessed tax.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude